The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nomogram based on multivariable regression model estimates the overall survival of patients with nivolumab who were previously treated for advanced non-small cell lung cancer.
 
Motohiro Tamiya
Honoraria - Asahi Kasei; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Ono Pharmaceutical
 
Akihiro Tamiya
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hirofumi Go
No Relationships to Disclose
 
Takako Inoue
No Relationships to Disclose
 
Madoka Kimura
No Relationships to Disclose
 
Kei Kunimasa
No Relationships to Disclose
 
Kenji Nakahama
No Relationships to Disclose
 
Yoshihiko Taniguchi
No Relationships to Disclose
 
Takayuki Shiroyama
No Relationships to Disclose
 
Shun-Ichi Isa
No Relationships to Disclose
 
Kazumi Nishino
Honoraria - Chugai Pharma
 
Toru Kumagai
No Relationships to Disclose
 
Hidekazu Suzuki
No Relationships to Disclose
 
Tomonori Hirashima
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shinji Atagi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Hisamitsu Pharmaceutical; Lilly Japan; MSD K.K; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Ayumi Shintani
No Relationships to Disclose
 
Fumio Imamura
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Ono Pharmaceutical